Morgenthaler Ventures is a venture capital firm based in Portola Valley, California, with over 45 years of experience in the industry. Founded in 1968, the firm focuses on investing across various sectors, including business-to-business (B2B), business-to-consumer (B2C), healthcare, information technology, software as a service (SaaS), manufacturing, and life sciences. Morgenthaler Ventures aims to partner with innovative companies and supports their growth through strategic guidance and substantial capital investment. The firm has a history of investing in notable IT companies, including Evernote, Lending Club, and Siri. In addition to its venture capital activities, Morgenthaler also engages in lower middle market private equity through Morgenthaler Private Equity, focusing on leveraged buyouts, recapitalizations, and investments in entrepreneurial and family-owned businesses. The firm seeks to create long-term shareholder value by collaborating closely with management teams to enhance operational and financial performance.
Ardian is a privately held, clinical-stage medical device company that develops catheter-based therapies for hypertension treatment and related conditions. It develops a catheter system that uses radio-frequency energy to “deactivate” sympathetic nerves in the kidneys, lowering blood pressure. The company's flagship product, the Symplicity Catheter System, addresses uncontrolled hypertension through renal denervation, or ablation of the nerves lining the renal arteries. It has received the CE (Conformité Européene) mark and Australia's Therapeutic Goods Administration (TGA) listing but is not yet approved by the U.S. Food and Drug Administration (FDA).
Ardian
Series B in 2006
Ardian is a privately held, clinical-stage medical device company that develops catheter-based therapies for hypertension treatment and related conditions. It develops a catheter system that uses radio-frequency energy to “deactivate” sympathetic nerves in the kidneys, lowering blood pressure. The company's flagship product, the Symplicity Catheter System, addresses uncontrolled hypertension through renal denervation, or ablation of the nerves lining the renal arteries. It has received the CE (Conformité Européene) mark and Australia's Therapeutic Goods Administration (TGA) listing but is not yet approved by the U.S. Food and Drug Administration (FDA).
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.